Yu F F, Xia C T, Fang H, Han J, Younus M I, Guo X
Institute of Endemic Diseases of School of Public Health, Health Science Center, Xi'an Jiaotong University, Key Laboratory of Environment and Genes Related to Diseases of Ministry of Education, Key Laboratory of Trace Elements and Endemic Diseases of Ministry of Health, Xi'an 710061, China.
Institute of Endemic Diseases of School of Public Health, Health Science Center, Xi'an Jiaotong University, Key Laboratory of Environment and Genes Related to Diseases of Ministry of Education, Key Laboratory of Trace Elements and Endemic Diseases of Ministry of Health, Xi'an 710061, China.
Osteoarthritis Cartilage. 2014 Jun;22(6):718-25. doi: 10.1016/j.joca.2014.04.012. Epub 2014 Apr 30.
To assess the efficacy and safety of intra-articular hyaluronic acid (IAHA) injection in knee joints of patients with Kashin-Beck disease (KBD).
We searched nine electronic databases as well as unpublished data from inception until November 30th 2013 using a combination of search terms for KBD and hyaluronic acid (HA). For dichotomous data, odds ratios (OR) and 95% confidence intervals (CI) were estimated. For continuous data, standard mean difference (SMD) was used for outcomes pooled on the difference scale using a "random-effects" or "fixed-effects" model. We also compared the mean and standard deviation of cytokine levels in post-treatment.
The seven eligible trials included 954 IAHA and 495 control patients. The methodological quality of included trials was low. The overall effectiveness of the IAHA group and control group were 93.7% and 62.9%, respectively. IAHA group resulted in very large treatment effects compared to pre-treatment values in 12 months, with SMD values ranging from 1.19-2.64 (all P < 0.05). Compared to controls, SMDs in IAHA group ranged from 0.19-0.64 at 1 week to 1 month (all P > 0.05) and 0.68-1.47 at 2 months to 12 months (all P < 0.05). There was significant improved of HA, cluster of differentiation44 (CD44), keratan sulfate (KS), interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α) and nitric oxide (NO) contents in serum compared with that in the post-treatment and healthy control in non-KBD area (all P < 0.05).
IAHA for the treatment of KBD was safe and efficacious at 12 months with low and transient adverse reactions. However, more high-quality randomized controlled trials (RCTs) are needed to confirm its therapeutic effect.
评估关节腔内注射透明质酸(IAHA)治疗大骨节病(KBD)患者膝关节的疗效和安全性。
我们检索了九个电子数据库以及从数据库建立至2013年11月30日的未发表数据,使用了大骨节病和透明质酸(HA)的组合检索词。对于二分数据,估计比值比(OR)和95%置信区间(CI)。对于连续数据,使用标准均数差(SMD)对采用“随机效应”或“固定效应”模型在差值尺度上汇总的结果进行分析。我们还比较了治疗后细胞因子水平的均值和标准差。
七项符合条件的试验纳入了954例接受IAHA治疗的患者和495例对照患者。纳入试验的方法学质量较低。IAHA组和对照组的总体有效率分别为93.7%和62.9%。与治疗前相比,IAHA组在12个月时产生了非常大的治疗效果,SMD值范围为1.19至2.64(所有P<0.05)。与对照组相比,IAHA组在1周时的SMD值范围为0.19至0.64,1个月时为0.19至0.64(所有P>0.05),2个月至12个月时为0.68至1.47(所有P<0.05)。与非大骨节病地区治疗后及健康对照相比,血清中透明质酸(HA)、分化簇44(CD44)、硫酸角质素(KS)、白细胞介素-1β(IL-1β)、肿瘤坏死因子-α(TNF-α)和一氧化氮(NO)含量均有显著改善(所有P<0.05)。
IAHA治疗大骨节病在12个月时安全有效,不良反应少且短暂。然而,需要更多高质量的随机对照试验(RCT)来证实其治疗效果。